Extensive clinical, hormonal and genetic screening in a large consecutive series of 46,XY neonates and infants with atypical sexual development

Dorien Baetens¹, Wilhelm Mladenov²,³, Barbara Delle Chiaie¹, Björn Menten¹, An Desloovere², Violeta Iotova³, Bert Callewaert¹, Erik Van Laecke⁴, Piet Hoebeke⁴, Elfride De Baere¹ and Martine Cools²*  

Abstract

Background: One in 4500 children is born with ambiguous genitalia, milder phenotypes occur in one in 300 newborns. Conventional time-consuming hormonal and genetic work-up provides a genetic diagnosis in around 20-40% of 46,XY cases with ambiguous genitalia. All others remain without a definitive diagnosis. The investigation of milder cases, as suggested by recent reports remains controversial.

Methods: Integrated clinical, hormonal and genetic screening was performed in a sequential series of 46, XY children, sex-assigned male, who were referred to our pediatric endocrine service for atypical genitalia (2007–2013).

Results: A consecutive cohort of undervirilized 46,XY children with external masculinization score (EMS) 2–12, was extensively investigated. In four patients, a clinical diagnosis of Kallmann syndrome or Mowat-Wilson syndrome was made and genetically supported in 2/3 and 1/1 cases respectively. Hormonal data were suggestive of a (dihydro) testosterone biosynthesis disorder in four cases, however no HSD17B3 or SRD5A2 mutations were found. Array-CGH revealed a causal structural variation in 2/6 syndromic patients. In addition, three novel NR5A1 mutations were found in non-syndromic patients. Interestingly, one mutation was present in a fertile male, underlining the inter- and intrafamilial phenotypic variability of NR5A1-associated phenotypes. No AR, SRY or WT1 mutations were identified.

Conclusion: Overall, a genetic diagnosis could be established in 19% of non-syndromic and 33% of syndromic cases. There is no difference in diagnostic yield between patients with more or less pronounced phenotypes, as expressed by the external masculinisation score (EMS). The clinical utility of array-CGH is high in syndromic cases. Finally, a sequential gene-by-gene approach is time-consuming, expensive and inefficient. Given the low yield and high expense of Sanger sequencing, we anticipate that massively parallel sequencing of gene panels and whole exome sequencing hold promise for genetic diagnosis of 46,XY DSD boys with an undervirilized phenotype.

Keywords: 46,XY DSD, Undervirilization, Integrated screening, Diagnosis, Array-CGH, MLPA, NR5A1 mutations

* Correspondence: martine.cools@ugent.be
²Department of Pediatric Endocrinology, Ghent University Hospital and Ghent University, Building 3K12D, De Pintelaan 185, 9000 Ghent, Belgium
Full list of author information is available at the end of the article
Background

The birth of a child with ambiguous genitalia is a rare event with a prevalence of one in 4500 live births and poses a challenge to the parents and the medical team [1]. Specialized multidisciplinary medical care, aiming at addressing concerns and uncertainties with regard to gender assignment, underlying etiology and management, as well as providing adequate psychological support is essential [2]. Extensive and time-consuming hormonal and genetic work-up provides a genetic diagnosis in 20-40% of cases [3,4]. Less pronounced atypical development of male external genitalia is more prevalent and is noticed in the newborn period in around one in 300 males; 75% of cases are associated with hypospadias [5]. These milder forms of undervirilization, such as isolated or combined cryptorchidism and hypospadias have been related to environmental factors, low birth weight and multiple gene polymorphisms rather than single gene mutations [6-8]. However, mutations in the Androgen Receptor (AR), Nuclear Receptor Subfamily 5 Group A Member 1 (NR5A1) and Wilms Tumor 1 (WT1) genes - classically associated with genital ambiguity or more severe forms of undervirilization - have recently been identified in cases with isolated proximal or even distal hypospadias, combined cryptorchidism and (distal) hypospadias or anorchia, and sequencing of these genes has been advocated in such cases [9-14]. On the other hand, copy number variations in genes involved in the process of sexual development have effectively been detected by whole genome (array comparative genomic hybridization, array-CGH) or targeted (multiplex ligation-dependent probe amplification, MLPA) copy number analysis [15-17], and both techniques have become widely available in recent years. However, whether a systematic extensive genetic work-up is indicated in the 46,XY newborn with a milder degree of undervirilization, such as indicated by a higher Prader or External Masculinization Score (EMS) remains a matter of debate [18]. Current screening methods are time consuming and have a low efficiency. The introduction of genome-wide technologies such as whole exome sequencing (WES) holds promise for future clinical decision making in a routine diagnostic setting for these rare, genetically heterogeneous conditions. In order to gain insight in the appropriateness and diagnostic yield of a systematic genetic work-up in 46,XY infants with atypical external genitalia, we performed a standardized genetic screening panel in all 46,XY newborns and infants who were referred to our pediatric endocrinology service for the evaluation of atypical genitalia (e.g. hypospadias, micropenis) and who were sex assigned male, between 2007–2013 were included (n = 32) (Table 1). Medical history included pregnancy details, birth weight (BW), consanguinity and a familial history of disorders of sex development (DSD), sub- or infertility, premature ovarian failure (POF) or atypical genitalia. Phenotypic description consisted of a physical examination with special attention to dysmorphism; EMS scores were calculated based on the aspect of the external genitalia [19]. None of the patients had proteinuria or renal insufficiency.

Patients and methods

Patients

All 46,XY children younger than two years who were referred to our pediatric endocrinology service for the evaluation of atypical genitalia (e.g. hypospadias, micropenis) and who were sex assigned male, between 2007–2013 were included (n = 32) (Table 1). Medical history included pregnancy details, birth weight (BW), consanguinity and a familial history of disorders of sex development (DSD), sub- or infertility, premature ovarian failure (POF) or atypical genitalia. Phenotypic description consisted of a physical examination with special attention to dysmorphism; EMS scores were calculated based on the aspect of the external genitalia [19]. None of the patients had proteinuria or renal insufficiency.

Methods

Biochemical analyses

Hormonal levels were obtained between day 14–90 after birth or after HCG stimulation (Pregnyl®, 1500U, with blood sampling at baseline and after 72 hours). The following hormone levels were measured: anti-Müllerian Hormone (AMH) by enzyme linked immunosorbent assay (Beckman Coulter Company), Androstenedione (A) by Radioimmunoassay (DiaSource Company), Testosterone (T) and Dihydrotestosterone (DHT) by liquid chromatography/tandem mass spectrometry (UPLC Waters quattro premie). LH and FSH by electrochemoluminescence assay (Roche Diagnostics E170 Modular).

Genetic analyses

Array-CGH using the Agilent 180 K array was used as a genomewide screen for copy number variations (CNVs) with an overall mean probe spacing of 14 kb, or 11 kb when only taking into account the Refseq genes. Hybridization was done according to the manufacturer’s protocol, followed by visualization of the results in arrayCGHbase [20]. fluorescent in situ hybridization (FISH) was performed for SRY to search for SRY rearranging translocations and mosaicism. To screen for CNVs on the exon level, MLPA was done using the SALSA MLPA P185 Intersex probemix (MRC-Holland) containing probes for NR0B1, NR5A1, SOX9, SRY and WNT4. Sanger sequencing of the

Region Y (SRY), SRY-box 9 (SOX9), Nuclear Receptor Subfamily 0 Group B Member 1 (NR0B1), Wingless type 4 (WNT4) and NR5A1. Additionally, sequencing of SRY was performed in cases with hormonal results consistent with the presence of (partial) gonadal dysgenesis, and sequencing of Hydroxysteroid (17-Beta) Dehydrogenase (HSD17B3) or Steroid-5-Alpha-Reductase, Alpha Polypeptide 2 (SRD5A2) was performed in cases with suspicion of a (dihydro)testosterone biosynthesis defect. Results were interpreted in the light of clinical and hormonal findings.
| Code | GA (weeks) | BW (g) | BW (SD) | EMS | Pregnancy | Dysmorphic features | Consanguinity | Family history |
|------|------------|--------|---------|-----|-----------|--------------------|---------------|----------------|
| 1    | 32         | 900    | −3.15   | 2/12| CS        | IUGR               | No            | Unremarkable   |
| 2    | 41         | 3,260  | −1.12   | 3/12| Normal    | Large ears, broad nose, mild frontal bossing | No            | Unremarkable   |
| 3    | 40         | 4,150  | 1.12    | 2.5/12 | Normal | /                | No            | Maternal aunt: difficulties to get pregnant, one child with congenital abnormalities |
| 4    | 41         | 3,060  | −1.6    | 3/12| Normal | /                | No            | Unremarkable   |
| 5    | 34         | 1,320  | −2.93   | 7.5/12 | CS | IUGR | No            | Unremarkable   |
| 6    | 40         | 3,380  | −0.59   | 9/12| Normal | /                | No            | Grandfather with hypospadias, maternal aunt with POF |
| 7    | 30         | 510    | −3.8    | 6/12| Induced delivery | IUGR | No            | Paternal grandmother: cleft lip |
| 8    | 39         | 3,690  | 0.45    | 10/12| IVF | /                | No            | Unremarkable   |
| 9    | 38         | 3,310  | 0.01    | 8/12| Normal | /                | No            | Unremarkable   |
| 10   | 39         | 2,850  | −1.53   | 9/12| Placental infarction | Microcephaly | No            | Unremarkable   |
| 11   | 40         | 3,000  | −1.51   | 3/12| Normal | Macrocephaly, facial dysmorphism, short neck, developmental delay (speech) | No            | Unremarkable   |
| 12   | 40         | 3,850  | 0.47    | 6/12| Normal | /                | Yes           | Mother: fertility problems, irregular menses |
| 13   | 35         | 2,530  | −0.26   | 6/12| Preeclampsia and hypertension | /                | No            | Unremarkable   |
| 14   | 32         | 945    | −2.98   | 3/12| Bleeding | /                | No            | Unremarkable   |
| 15   | 40         | NA     | NA      | 3/12| Normal | /                | No            | Unremarkable   |
| 16   | 28         | 860    | −1.26   | 7/12| Eclampsy | Atrial septum defect | No            | Unremarkable   |
| 17   | 34         | 1,450  | −2.52   | 6/12| Prematurity | Ventricular septum defect | Yes           | Cousin (deceased) with Jeune syndrome |
| 18   | 34         | 1,400  | −2.68   | 2/12| CS | /                | No            | Unremarkable   |
| 19   | 41         | 2,805  | −2.24   | 3/12| Normal | /                | No            | Unremarkable   |
| 20   | 39         | 2,880  | −1.45   | 6/12| Normal | /                | Possible      | Unremarkable   |
coding exons and untranslated regions (UTRs) was used to identify mutations in AR, NR5A1 and WT1. SRY sequencing was included for patients suspected to have gonadal dysgenesis, based on an AMH level below the reference range. HSD17B3 and SRD5A2 were sequenced in cases with suspicion of a testosterone biosynthesis disorder based on a T/A ratio <1 for 17β-HSD deficiency and a T/DHT ratio > 8.5 for 5α Reductase Deficiency (Table 2) [21,22]. Primers for AR, WT1 en SRY were designed using PrimerXL (http://www.primerxl.org/, available on request). Primer sequences for NR5A1, HSD17B3 and SRD5A2 can be found in supplemental data (Additional file 1: Table S1). Zinc Finger E-Box Binding Homeobox 2 (ZEB2) sequencing and sequencing of the Kallmann syndrome (KS) gene panel, consisting of six genes (KAL1, CHD7, FGFR1, PROK2, PROKR2, FGF8) was done at the Henri Mondor Hospital (Paris, France). Fibroblast Growth Factor Receptor 1 (FGFR1) sequencing was performed at the CHU Hospital Cochin (Paris, France).

**Table 1 Medical history and phenotypic details of patients (Continued)**

| No. | Age (y) | GA (d) | BW (g) | EMS | POF | SIDS | CS | IVF | Twins | Placental rupture | Preterm contractions | Preeclampsia | Normal | Previous abortions | X-linked ichthyosis | Hypotonia | Developmental delay ductus arteriosus | Persisting | Abnormal liver function tests | Father: late puberty | Maternal grandfather: depression | Maternal grandmother: recurrent miscarriage | Father: late puberty | Paternal uncle: retractile testes, normal fertility |
|-----|---------|-------|-------|-----|-----|------|----|-----|-------|-------------------|---------------------|-------------|-------|-------------------|---------------------|----------|--------------------------|-----------|------------------------|------------------|-----------------------------|----------------------|------------------------------|------------------|-----------------------------|
| 21  | 36      | 1585  | −3.39 | 7/12| /   | No   | /   | /   |       |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 22  | 39      | 2640  | −2.07 | 6/12| /   | No   | /   | /   |       |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 23  | 40      | 3250  | −0.9  | 8/12| /   | No   | /   | /   |       |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 24  | 37      | 3290  | −0.43 | 6/12| /   | Yes  | /   | /   |       |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 25  | 38      | 2800  | −1.20 | 6/12| /   | No   | /   | /   |       |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |

Table 1 Medical history and phenotypic details of patients (Continued)

| No. | Age (y) | GA (d) | BW (g) | EMS | POF | SIDS | CS | IVF | Twins | Placental rupture | Preterm contractions | Preeclampsia | Normal | Previous abortions | X-linked ichthyosis | Hypotonia | Developmental delay ductus arteriosus | Persisting | Abnormal liver function tests | Father: late puberty | Maternal grandfather: depression | Maternal grandmother: recurrent miscarriage | Father: late puberty | Paternal uncle: retractile testes, normal fertility |
|-----|---------|-------|-------|-----|-----|------|----|-----|-------|-------------------|---------------------|-------------|-------|-------------------|---------------------|----------|--------------------------|-----------|------------------------|------------------|-----------------------------|----------------------|------------------------------|------------------|-----------------------------|
| 26  | 39      | 3770  | −0.63 | 12/12| /   |       | /   | /   |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 27  | 26      | 700   | −1.26 | 10/10| /   |       | /   | /   |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 28  | 36      | 2570  | −0.72 | 8/12| /   |       | /   | /   |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 29  | 39      | 3230  | −0.6  | 9/12| /   |       | /   | /   |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 30  | 38      | 3782  | 1.04  | 8/12| /   |       | /   | /   |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |
| 31  | 39      | 2780  | −1.70 | 12/12| /   | No   | /   | /   |       |                   | 10/10              |             |       |                   |                     |           |                          |           |           | /                | /                  |                       | /                    |                       | /                  | /                           |                     |                             |

GA: gestational age, BW: birth weight, EMS: external masculinization score, IUGR: intra uterine growth retardation, POF: premature ovarian failure, SIDS: sudden infant death syndrome; CS: Caesarian section, IVF: in vitro fertilization.

**Cell culture, RNA extraction and cDNA synthesis**

Lymphocytes were isolated by Lymphoprep™ (STEMCELL Technologies) and cultured in RPMI medium with 10% FCS; interleukin-2 and phytohemagglutin were added. Cells were incubated at 37°C and 5% CO2. RNA was extracted using the RNeasy Plus Mini kit (Qiagen), followed by cDNA synthesis with the iScript™ cDNA synthesis kit (Biorad). Analysis of rt-qPCR results was done with qbase + software (Biogazelle).

**Expression analysis**

Expression levels of NR5A1 were measured through real-time quantitative PCR (rt-qPCR), using following primers: NR5A1-F 5’ caggaggttgcgcctca 3’ and NR5A1-R 5’ agttgcagcaggttcgca 3’. After in silico validation primers were tested using a dilution series. The experiment was done with the SsoAdvanced SYBR supermix (Bio-rad). Analysis of rt-qPCR results was done with qbase + software (Biogazelle).
| Code | FSH (U/l) | AMH (μg/l) | T (ng/dl) | AR | NR5A1 | WT1 | SRY | Array-CGH | MLPA | Other |
|------|-----------|------------|----------|----|-------|-----|-----|------------|------|-------|
| 1    | 14.0(1–12)| 62.7(46.8-173) | 43.8/ 579** | / | Ni    | Ni  | Ni  | FISH      | Ni   | HSD17B3 |
| 2    | 1.6(1–12) | 118(46.8-173) | 63.8/ 579** | / | c.253_254del | /  | Ni  | /          |      |       |
| 3    | NA        | 152(67.4-197) | 526**    | Ni | c.437G > C (tolerated) | /  | FISH | /          |      |       |
| 4    | 3.3(1–12) | 645(62–130)  | 184**    | Ni | c.630_637del | /  | FISH | /          |      |       |
| 5    | 7.6(105–270) | 222*       | Ni  | Ni  | Ni  | Ni  | /    | 7q36.3q36.3 (158189154–158343770)x1, maternal | Ni   |       |
| 6    | NA        | 106(38–180) | 275**    | Ni | Ni  | Ni  | Ni  | /          |      |       |
| 7    | NA        | 231(46.8-173) | NA     | Ni | Ni  | Ni  | /    | Xp22.33p22.33 (839417–1179089)x3, maternal | Ni   |       |
| 8    | NA        | 244(46.8-173) | NA     | Ni | Ni  | Ni  | Ni  | /          |      |       |
| 9    | 5.5(1–12) | 158*/511** | /       | /  | /    | /   | /    | 3p25(RP11-385A18 → RP11-334 L22)x3, 9p24.3 (RP11-48 M17 → RP11-320E16)x1 | Ni   |       |
| 10   | 2.5(1–12) | 147(46.8-173) | 109*    | Ni | Ni  | Ni  | /    | /          |      |       |
| 11   | NA        | 72.7(46.8-173) | 280*    | Ni | Ni  | FISH | Ni  | /          |      |       |
| 12   | 1.2(1–12) | 8.6(105–270) | 248*    | Ni | /    | /   | /    | /          |      |       |
| 13   | NA        | 132.9(42–185) | NA     | Ni | c.1109 G > A (p Cys370Tyr) | /  | FISH | /          |      |       |
| 14   | 1.3(1–12) | 298(67.4-197) | 337*    | Ni | Ni  | Ni  | FISH | /          |      |       |
| 15   | NA        | 72(38–180)  | NA     | Ni | Ni  | FISH | Ni  | /          |      |       |
| 16   | 2.6(1–12) | 82.2(23.8-124) | NA    | Ni | Ni  | Ni  | /    | 2p16.3p16.3 (5073244–5089436)x1; 16p13.11p13.11 (15830681–16270149)x3 | Ni   |       |
| 17   | 1.8       | 49.1(23.8-124) | 35.3*/ 390** | Ni | Ni  | Ni  | FISH | /          |      |       |
| 18   | 2.8(1–12) | 194(105–270) | 104*    | Ni | Ni  | Ni  | FISH | /          |      |       |
| 19   | 1.9(1–12) | 28.8(55.3-187) | NA     | Ni | Ni  | Ni  | /    | /          |      |       |
| 20   | 2.1(1–12) | 94.1(105–270) | 151*    | Ni | Ni  | Ni  | /    | 5p14.3p14.3(21438696–21490654)x1, maternal, 14q21.2q21.34208541–43293564)x3, maternal | Ni   |       |
| 21   | NA        | 11.27(55.3-187) | NA     | Ni | 404** | Ni  | Ni  | /          |      |       |
| 22   | NA        | 43(105–270)  | 152*/474** | /  | /    | /   | /    | /          |      | SRD5A2 N  |
| 23   | NA        | 156(105–270)  | 207.3*  | Ni | Ni  | Ni  | /    | /          |      |       |
| 24   | 0.17(1–12) | /       | /       | /  | /    | /   | /    | /          |      |       |
Table 2 Hormonal and genetic data of patients (Continued)

| Patient ID | Conceptions | Gestational age | Chorionic gonadotropin | Testosterone | AMH | FSH | LH | T/C | T/DHT | T/A | ±SD | ±SD | Genotype | Genotype |
|------------|-------------|----------------|------------------------|--------------|------|-----|----|-----|--------|------|------|------|-----------|-----------|
| 27         | NA          | 65.9(105–270)  | 3.3*90.8                | /            | /    | /   | /  | /   | /      | /    | /    | /    | **        | **        |
| 28         | NA          | 245(55.3–187)  | 951**                  | /            | /    | /   | /  | /   | /      | /    | /    | /    |           |           |
| 29         | 0.57(1–12)  | 14.03 (55.3–187)| NA                     | /            | /    | /   | /  | /   | /      | /    | /    | /    | Xp22.32p22.31(540569–9222059)x0, maternal | /         |
| 30         | 1.2(1–12)   | 159(105–270)   | 502*                   | /            | /    | /   | /  | /   | /      | /    | /    | /    | FGFR1 c.1042G>A | ZEB2 c.2856delG |
| 32         | 11(1–12)    | 25(105–270)    | 191.9*                 | /            | /    | /   | /  | /   | /      | /    | /    | /    |           |           |

Symbols and abbreviations: NA not available, FSH follicle stimulating hormone, AMH anti-Müllerian hormone, ref age-specific reference value, T testosterone, Nl normal.

* Determined between day 14–90; $: age-specific AMH reference values may differ according to the commercial kits that have been used during the course of the study; **Basal testosterone value between day 14–90; T Testosterone value after HCG stimulation (1500 U, blood sampling after 72 h).

Genomic coordinates based on build hg18 (2006), except for patient 32, where build hg19 (2009) is used.

The study was approved by the local medical ethical committee (Registration number B670201110608) and all parents signed a written informed consent.

**Results**

**Clinical investigation**

Consanguinity was present or suspected in 4/32 cases (12.5%). Another four cases had a family history of subfertility or atypical genitalia. Nine children (28.1%) were born small for gestational age (SGA), defined as a BW < −2 Standard Deviation (SD) for gestational age, with a mean BW of −2.8 SD; mean BW of children born appropriate for GA was −0.36 SD. EMS scores ranged from 2/12 to 12/12. In 6/32 children (18.7 %) dysmorphic features were noticed. Patient details are represented in Table 1.

Three out of 32 patients (P26, P28, P29) were diagnosed with KS based on clinical and hormonal data (day 14–90). Patient 26 (EMS 12) was referred for an atypically looking short penis (with bilateral descended testes). At physical examination, stretched penis length (SPL) measured 30 mm, but his penis was extremely thin and weak, reminiscent of agenesis of the corpora cavernosa, which was excluded by Magnetic Resonance Imaging (MRI) of the penile structures. Hormonal data concordant with hypogonadotropic hypogonadism (HoH) (Table 2) and MRI revealing a hypoplaston bulbous olfactorius were both consistent with a diagnosis of Kallmann syndrome. An etiological diagnosis was sought by targeted resequencing of several known KS genes (KAL1, FGFR1, FGF8, CHD7, PROK2, PROKR2, H56ST1, WDR11, SEMA3A, NR5H1, NRHNR, KISS1, KISS1R, TAC3 and TACR3); no causal mutations were identified. The second patient with KS (P28, EMS 8) presented with mild craniofacial dysmorphism (ptosis, plagiocephaly), general hypotonia, developmental delay, microgenis (SPL 15 mm) and bilateral inguinal testes. Low gonadotrophins in association with a low AMH was suggestive of HoH. Array-CGH revealed a causal hemizygous deletion on the X chromosome including the Kallmann syndrome 1 (KAL1) gene, as discussed below. Patient 29 (EMS 9) was diagnosed with KS based on the presence of microgenis (SPL 21 mm) and a positive family history for KS: the father had been diagnosed with KS and was able to conceive following gonadotrophin therapy. Hormonal data confirmed HoH in the index patient. The diagnosis was supported genetically by the identification of a heterozygous FGFR1 mutation, c.1042G>A (p.G348R), in both the patient and his father. This mutation has been described previously [23].

Patient 30 was diagnosed with Mowat-Wilson syndrome (MWS), he presented with typical external ear abnormalities (Figure 1), hypotonia, persistent ductus arteriosus, ventricular septum defect, facial dysmorphism, Hirschsprung disease, penoscrotal inversion and hypospadias. MWS is caused by heterozygous de novo mutations in ZEB2. Sequencing of this gene revealed a heterozygous one basepair frameshift deletion, c. 2856delG (p.Arg953Glufs*24).

**Hormonal work-up**

With the exception of cases with KS, where FSH was low, serum FSH was within the reference range in all cases. AMH, representing Sertoli cell function, was low in 11/32 cases (34,3%), including 2/3 cases with KS (in the third KS case, AMH could not be determined) and 4/9 cases (44%) born SGA. Low AMH was associated with low T values (a marker for Leydig cell function) in only two cases (P3, subsequently diagnosed with a NRSAI mutation and P26, with KS). Two of three patients with NRSAI mutations had an AMH value within the reference for age. Ratios of T/A and T/DHT were determined to identify possible cases of (dihydro)testosterone biosynthesis disorders. The T/A ratio, measured
during mini-puberty was suggestive of 17β-HSD deficiency in two patients (case 1: T/A ratio 0.19; case 2: T/A ratio 0.52) and after HCG stimulation in one case (case 17: T/A ratio 0.08) [21,22]. HSD17B3 sequencing was performed in all three cases but revealed no causal mutations. In patient 2 a heterozygous missense variant was identified, c. 866G > A (p.Gly289Asp), although mutation prediction programs indicated this variant to be tolerated. In patient 24, a T/DHT ratio of 10.8 was found at basal sampling during mini-puberty but SRD5A2 sequencing revealed no mutations.

Genetic work-up

Array-CGH was done in 23/32 patients to screen for larger genomic rearrangements. In 10 of them, CNVs were identified as shown in Table 2. Seven of these rearrangements were maternally inherited, making their clinical significance questionable. In patient 11, we identified a partial chromosome 9 deletion (9p24.3), encompassing the Doublesex and Mab3 related transcription factor 1 (DMRT1) gene. In patient 28, a deletion was found on the X chromosome (Xp22.31-Xp22.32). This region includes the STS region and the genes KAL1 and Neuroligin 4, X-linked (NLGN4X). This deletion was also present in the patient’s mother. In addition, we performed MLPA for 23/32 patients to screen for deletions and/or duplications on the exon level, however no additional CNVs were identified.

AR (20/32) and WT1 (22/32) sequencing did not reveal any mutations. NRS5A1 sequencing was done in 26/32 patients, leading to the identification of three novel mutations, which will be discussed below. In cases with serum AMH below the reference value for age (8/32), suggestive of gonadal dysgenesis, SRY was sequenced, however no mutations were found.

Identification of three novel NRS5A1 mutations

NRS5A1 sequencing revealed three novel mutations (Figure 2A). In patient 3 a heterozygous frameshift deletion was identified: c.253_254del, resulting in a premature stop codon (p.Ala85*). No other family members were available for segregation analysis. A second heterozygous frameshift deletion of 8 bp was identified in patient 6, c.630_637del, (p.Tyr211Profs*12). Rt-qPCR in the patient’s lymphoblasts indeed showed a lower expression of NRS5A1 mRNA (Figure 2B). Segregation analysis indicated that this mutation was present in (1) the asymptomatic patient’s mother, (2) maternal aunt, who had been diagnosed with POF at the age of 35, and (3) grandfather, who had been operated for proximal hypoplasias, but spontaneously fathered two children (pedigrees in Figure 2C). The third mutation was found in patient 15, c.1109 G > A, (p.Cys370Trp). This mutation was predicted to have a deleterious effect on protein function according to several prediction programs (SIFT, Polyphen and MutationTaster). The affected amino acid is located in the ligand-binding domain and is highly conserved (up to zebrafish). Segregation analysis revealed that the mutation was present in the patient’s mother, who had no symptoms of POF at the age of 24.

Discussion

To gain insight into the appropriateness and diagnostic yield of a systematic integrated work-up in 46,XY undervirilized cases who are sex-assigned male, we used a standardized screening panel in a series of 32 cases referred to our DSD clinic. An overview of the approach is shown in Figure 3A. Difficulties in blood collection in newborns and infants made it impossible to perform the complete screening in every case, resulting in missing data. Low EMS scores (EMS < 7, n = 17) did not yield a higher diagnostic success as compared to higher EMS scores (EMS ≥ 7, n = 15). As reported earlier, no causal genetic variations were identified in children born SGA (n = 9) in our series [24].

Clinical investigation and hormonal data were sufficient to diagnose Kallmann syndrome and Mowat-Wilson syndrome in respectively three and one patients

Familial, hormonal and/or phenotypic data were sufficient to suspect KS in three patients (P26, 28 and 29) and MWS
Figure 2 (See legend on next page.)
in patient 30. As suggested in a paper by Grumbach et al., our study confirms that in boys, the period of physiological gonadotrophin surge (the so-called “mini-puberty”) represents a unique opportunity to diagnose KS early in cases with a suggestive phenotype (micropenis +/- cryptorchidism in the absence of hypospadias) [25]. In these patients a targeted approach to identify the underlying molecular cause was used. Here, we ended up with a higher diagnostic success rate, the molecular cause was identified in 75% (3/4) of patients. Despite suggestive hormonal results, we could not identify any HSD17B3, SRD5A2 or SRY mutations. Accumulation of A or T due to 17β-HSD deficiency or 5α-reductase deficiency respectively may lead to markedly low T/A (in case of 17β-HSD deficiency) or elevated T/DHT (in case of 5α-reductase deficiency) ratios. In contrast to previous reports, sequencing of the HSD17B3 and SRD5A2 genes in cases with aberrant T/A and T/DHT ratios respectively revealed no mutations [21,22,26,27]. However, for practical reasons, stimulated A
and T values, which are generally considered more accurate than basal values during mini-puberty, had been obtained in only one of three patients with T/A < 1. Another possible explanation might be the different detection methods used for the various androgens (Radioimmunoassay for A versus LC/MSMS for T). Simultaneous detection of A, T and DHT by LC/MSMS, as described recently, is expected to be more reliable but is not routinely available yet [28]. Low serum AMH has been reported previously in infants with KS [3,29], and has been attributed to a lack of FSH-driven stimulus [30,31].

In all cases in which serum AMH was below the age-specific reference values (n = 10), sequencing of SRY was performed but revealed no mutations, confirming that SRY mutations are a relatively rare cause of 46,XY partial gonadal dysgenesis in contrast to 46,XY complete gonadal dysgenesis, where SRY mutations are thought to account for up to 15% of cases [3,32].

**Genetic screening: targeted resequencing and copy number analysis**

Following a number of recent reports in which NR5A1, AR and WT1 mutations and CNVs have been identified as the cause of isolated hypospadias and/or cryptorchidism [10,12,33–39], a standardized genetic screening protocol was applied to identify the underlying genetic cause of the observed atypical genital development in all cases where clinical and hormonal data did not suggest a specific diagnosis, irrespective of the EMS scores. The screening consisted of array-CGH, MLPA and SRY-specific FISH to screen for genomic rearrangements, and sequencing of the AR, WT1 and NR5A1 genes.

**Array-CGH is a valuable diagnostic tool in 46,XY undervirilization newborns with dysmorphic features and allowed the identification of two causal CNVs in our cohort**

Array-CGH was used to screen for larger genomic rearrangements and led to the identification of two deletions with clinical significance, both found in syndromic patients. Patient 11 (EMS = 3) presented with penoscrotal hypospadias and transposition. Besides these genital characteristics, this patient also showed macrocephaly, facial dysmorphism and developmental delay. Hormonal results revealed normal T levels, AMH was not available; array-CGH revealed a partial chromosome 9 deletion, encompassing the DMRT gene cluster. These genes encode transcriptional regulators involved in sex development, and monosomy of the distal part of chromosome 9p, mostly DMRT1, has been associated with 46,XY DSD in several cases [40,41]. Patient 28 (EMS = 8) showed symptoms of KS. Other phenotypic characteristics included: X-linked ichthyosis, hypotonia, recurrent kidney stones and developmental delay. Liver function tests showed abnormal results, of hitherto unknown etiology. In this patient a part of the X-chromosome, including the genes KAL1 and NLGN4X, was deleted. KAL1 deletions or mutations are an established cause of X-linked KS and can explain the genital phenotype seen in this patient [42]. NLGN4X, has been associated with X-linked mental retardation and X-linked autism spectrum disorders [43], and might explain the observed developmental delay. Previously, a link between KS, ichthyosis and Xp deletions has been described by Bick et al. [44]. No evident association could be found between the identified deletion and the elevated liver enzymes and recurrent kidney stones. This deletion was inherited from the mother, who had mild mental delay but no symptoms of KS. This deletion is therefore characterized by incomplete penetrance.

In total, array-CGH revealed 10 CNVs in 22 patients, seven of them were inherited from the mother; making their clinical relevance questionable. Array-CGH resulted in a definite genetic diagnosis in 2/22 patients, (9%). When only considering the syndromic cases, array-CGH renders a diagnostic yield of 2/6 patients (33%). Although our series is small we can conclude that array-CGH is a valuable diagnostic tool in 46,XY DSD with associated dysmorphic features however larger patient groups should be investigated to make more definite conclusions. Because of the limited resolution of array-CGH, we performed MLPA to screen for deletions or duplications on the exon level for SOX9, NR5A1, WNT4 and NR0B1. In total 23 patients were screened, however no additional CNVs were identified. Likewise, FISH analysis of SRY could not reveal any deletions. Although the mutation uptake of targeted CNV detection (MLPA) was limited in our cohort, it still remains an important addition to a genetic work-up of 46,XY undervirilized or 46,XY DSD patients. Different reports showed NR5A1 microdeletions as a cause of both 46,XY DSD and POF [16,45].

**We identified three novel NR5A1 mutations, one of them was present in an affected male with preserved fertility**

Recently Kohler et al. reported a WT1 mutation rate of 7.5% in children with severe hypospadias and Wang et al. identified AR mutations in 6.6% of their patient cohort with isolated hypospadias and micropenis, indicating a role for both WT1 and AR in minor forms of undervirilization [4,34]. Sanger sequencing of AR and WT1 was done in respectively 20 and 22 patients of our cohort. In contrast to these series, no significant sequence changes in these genes were identified. The relatively high frequency in previous cohorts might be attributed to a selection bias. Therefore, we conclude that the incidence of mutations in AR and WT1 mutations is probably overestimated in patients with milder forms of undervirilization. On the other hand, NR5A1 was sequenced in 26 patients and revealed mutations in
three of them (11.5%). This is in line with other series, where mutations were identified in approximately 15% of patients. In our cohort, two frameshift mutations and one missense mutation were identified. The missense mutation, c.1109G > A, found in patient 15 (EMS = 3), targets an amino acid in the functionally important ligand and binding domain (p.Cys370Tyr) and is predicted to alter protein function (SIFT, Polyphen, MutationTaster). This mutation was also found in the patient's mother. In addition to causing 46,XY DSD, NR5A1 mutations are a known cause of premature ovarian failure (POF) [46]. The patient's mother had regular menses at the age of 30, however she is at risk for developing POF. The first frameshift mutation (patient 3), c.253_254del induces a premature stop codon at position 85 (p.Ala85*). There were no additional family members available for segregation analysis. The second frameshift mutation (patient 6), c. 630_637del, also leads to a premature stop codon (p. Tyr211Profs12*). This mutation was also present in the mother of the patient, a maternal aunt and the maternal grandfather. The aunt had recently been diagnosed with POF at the age of 35 years and underwent several in vitro fertilization (IVF) cycles, the patient's mother (age 39) declared to have regular menses. Interestingly, the grandfather had been treated for hypospadias as a child. Preserved fertility in males with NR5A1 mutations has only exceptionally been reported so far [47,48]. These findings support the extreme intrafamilial variability seen with NR5A1 mutations. At the moment the mechanism behind this phenotypic variability and incomplete penetrance resulting from NR5A1 mutations remains elusive; they likely result from the effects of multiple genetic variations (modifiers) and/or their interactions with environmental factors. Variable expressivity, reduced penetrance and even more complex inheritance patterns such as digenic models have been reported in other developmental conditions such as Kallmann syndrome and may be explained in part by the overall ‘mutational load’ in different genes playing a role in common signaling pathways [49-51].

The integrated story: clinical, hormonal and genetic data

Taken together, in spite of extensive clinical, hormonal and genetic screening, the molecular cause of 46,XY atypical male genital development could only be identified in seven out of 32 patients (21.8%). When comparing the diagnostic success rate between patients with low (<7, n = 17) or high (≥7, n = 15) EMS scores, we identified the underlying molecular defect in respectively three and four patients, leading to a diagnostic success rate of respectively 17.6% and 26.5% for patients with low versus higher EMS scores, suggesting that the decision to perform a detailed diagnostic work-up in 46,XY patients with atypical genitalia should not be based on the severity of the phenotype alone. Array-CGH revealed the causal CNV in two out of six syndromic patients, leading to a diagnostic yield of 33% in patients with additional phenotypic characteristics. When we included non-syndromic cases, the success rate drops to 9%, indicating that array-CGH is still an appropriate diagnostic tool in syndromic forms of 46,XY DSD, but is less efficient in non-syndromic cases. Sequencing of AR, WT1 and SRY did not reveal any mutations. Besides the low diagnostic yield of this sequential sequencing approach, cost and time efficiency should be considered. Sanger sequencing has an average cost of $2400 per million bases, whereas the emerging next generation sequencing technologies (NGS) are much cheaper. With the Illumina platform, there is only a $0.07 sequencing cost per million bases (number based on HiSeq2000) [52]. The next step in the diagnostic work-up of 46,XY boys with atypical genitalia should be the implementation of targeted NGS panels covering clinically relevant genes with a known role in sex development and steroid biosynthesis pathways. A flexible and automated NGS workflow used for targeted resequencing of disease gene panels has been reported by us and allows parallel and cost-effective analysis of a sizeable number of genes in a clinical setting (De Leeneer et al. Human Mutation provisionally accepted). While this approach seems to be very useful in some heterogeneous disorders, their clinical utility in 46,XY DSD is debatable, since the known disease genes in these phenotypes only account for 20–40% of patients. Therefore we anticipate that whole exome sequencing (WES), which is increasingly put forward as a clinical diagnostic test in genetically heterogeneous disorders [53,54], will gain importance in the diagnostic work-up of 46,XY DSD, both in a clinical and research context. However, in cases where associated phenotypic characteristics or cases where clinical and hormonal data suggest a specific gene defect, it remains advisable to perform targeted resequencing of the specific disease gene(s).

Conclusion

In this study we examined a large consecutive cohort of undervirilized 46,XY neonates and infants. Following this protocol we were able to genetically diagnose 19% of non-syndromic patients and one third of the syndromic cases. There was no significant difference between the diagnostic success rate in patients with low EMS compared to higher EMS. In syndromic cases, array-CGH had a high diagnostic yield. Serial gene screening resulted in several novel NR5A1 mutations, although the overall diagnostic yield was rather low. Interestingly, we identified a novel NR5A1 mutation that was
also present in a related male with preserved fertility, which has only exceptionally been reported. Given the low diagnostic yield of the sequential approach, parallel screening technologies such as targeted resequencing of clinically relevant disease genes and WES will be a preferred choice in future screening protocols. However, in cases where associated phenotypes are present, a more targeted approach remains the preferential strategy.

Additional file

**Additional file 1: Table S1.** Overview of the primer sequences for NR5A1 (NM_004959.4), HSD17B3 (NM_000197.1) and SDF5 (NM_000348.3).

**Abbreviations**

A: Androstenedione; AMH: Anti-Müllerian hormone; Array-CGH: Array-comparative genomic hybridization; CNV: Copy number variant; DSD: Disorders of sex development; DHT: Dihydrotestosterone; EMS: External masculinization score; FISH: Fluorescent in-situ hybridization; FF: Follicle stimulating hormone; H: Hypergonadotropic hypogonadism; IFV: In-vitro fertilization; KS: Kallmann syndrome; LH: Luteinizing hormone; MLPA: Multiplex ligation dependent probe amplification; MWS: Mowat-Wilson syndrome; POF: Premature ovarian failure; Re-qPCR: Real-time quantitative PCR; SD: Standard deviation; UTR: Untranslated regions; WES: Whole exome sequencing.

**Competing interests**

The authors declare that they have no competing interests.

**Authors' contributions**

MC and DB were involved in writing of the manuscript. All other authors participated in revision of the draft. DB, EDB and BM conducted and MC and DB were involved in writing of the manuscript. All other authors contributed to the final manuscript.

**Acknowledgements**

We are most grateful to the patients, and their families, who participated in this study and to the referring clinicians who made this work possible. We thank Dr. Fiers for the execution of the biochemical tests. DB is supported by a Special Research Fund (BOF) grant from the Ghent University. MC and EDB are supported by a Senior Clinical Investigator grant from the Flemish Government. All authors read and approved the final manuscript.

**References**

1. Thyen U, Lanz K, Holterhus P-M, Hiort O. Epidemiology and initial management of ambiguous genitalia at birth in Germany. Horm Res 2006, 66:195–203.
2. Brain CE, Paediatric C, Creighton SM, Muhttap I, Glasg P, Paed F, Clinical C, Banicott A: Holistic management of DSD. Best Pract Res Clin Endocrinol Metab 2010, 24:335–354.
3. Ono M, Harley VR: Disorders of sex development: new genes, new concepts. Nat Rev Endocrinol 2013, 9:79–91.
4. Köhler B, Biebigmann H, Friedsam V, Gellermann J, Maier RF, Pohl M, Weacker P, Hiort O, Grüters A, Krude H. Analysis of the Wilms' tumour suppressor gene (WT1) in patients 46, XY disorders of sex development. J Clin Endocrinol Metab 2011, 96:E1131–E1136.
5. Ahmed SF. Prevalence of hypospadias and other genital anomalies among singleton births, 1988–1997, in Scotland. Arch Dis Child Fetal Neonatal Ed 2004, 89:145–151.
6. Toppini J, Virtanen HE, Main KM, Skakkebaek NE. Cryptorchidism and hypospadias as a sign of testicular dysgenesis syndrome (TDS): environmental connection. Birth Defects Res A Clin Mol Teratol 2010, 88:910–919.
7. Van der Zanden LFM, Van Rood IAM, Felz WFJ, Knight J, Donders ART, Renkema KY, Borgers EMHF, Vermeulen SHMH, Kemeney LALM, Volman JA, Arias-Vázquez A, Zhang X, Markung J, Qiao L, Baskin LS, Nordensjöld A, Rooeveld N, Franke B, Knoers NVAM. Common variants in DGKK are strongly associated with risk of hypospadias. Nat Genet 2011, 43:485–90.
8. Sharpe RM. Sperm counts and fertility in men: a rocky road ahead. Science & Society Series on Sex and Science. EMBO Rep 2012, 13:98–403.
9. Hughes JA, Martin H, Jäskeläinen J. Genetic mechanisms of male undermasculinization: a background to the role of endocrine disruptors. Environ Res 2006, 100:44–9.
10. Köhler B, Lin L, Mazen I, Cetindag C, Biebigmann H, Akkurt I, Rossi R, Hiort O, Grüters A, Achromer JC. The spectrum of phenotypes associated with mutations in steroidogenic factor 1 (SF-1, NR5A1, AD4BP) includes severe penoscrotal hypospadias in 46, XY males without adrenal insufficiency. Eur J Endocrinol 2009, 161:237–242.
11. Ferraz-de Souza B, Lin L, Achromer JC. Steroidogenic factor-1 (SF-1, NR5A1) and human disease. Mol Cell Endocrinol 2011, 336:198–205.
12. Allali S, Müller J-B, Brauner R, Lourenço D, Boudjene R, Karageorgou V, Trivin C, Lottmann H, Trivin C, Lottat-Jacob S, Nihoul-Fekete C, De Dreux O, McIlreavey K, Barbashnoo A. Mutation analysis of NR5A1 encoding steroidogenic factor 1 in 77 patients with 46, XY disorders of sex development (DSD) including hypospadias. PLoS One 2011, 6:e22941.
13. Brauner R, Neve M, Allali S, Trivin C, Lottmann H, Barbashnoo A, McIlreavey K. Clinical, biological and genetic analysis of anorachy in 26 boys. PLoS One 2011, 6:e22929.
14. Köhler B, Schumacher V, Fallmerand D, Rayer-Pokora B, Grütters A. Germline Wilms tumour suppressor gene (WT1) mutation leading to isolated genital malformation without Wilms tumour or nephropathy. J Pediatr 2001, 138:421–424.
15. Ledig S, Hiort O, Scherer G, Hoffmann M, Wolf G, Mörloth S, Kuechler A, Weacker P: Array-CGH analysis in patients with syndromic and non-syndromic XY gonadal disorder of sex development. PLoS One 2010, 5:e10291.
16. Bellaro B, Viggiani M, Geoghegan J, Echeverria H, Vermeulen S, Wolf G, Mörloth S, Kuechler A, Weacker P. Clinical, biological, and molecular genetic findings in patients with 17α-hydroxylase deficiency. Sperm counts and fertility in men: a rocky road ahead. Science & Society Series on Sex and Science. EMBO Rep 2012, 13:98–403.
17. Menten B, Pattyn F, De Preter K, Robrecht P, Michels E, Buysse K, Mortier G, De Peene S, De Schrijver F, Vandesompele J. arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics 2005, 6:124.
18. Twesten W, Holterhus P, Sippell WG, Morlot F, Schumacher H, Schenk BHO. Clinical, endocrine, and molecular genetic findings in patients with 17 beta-hydroxysteroid dehydrogenase deficiency. Horm Res 2003, 23:463–464.
19. Ahmed SF, Rodie M. Investigation and initial management of ambiguous genitalia. Best Pract Res Clin Endocrinol Metab 2010, 24:197–218.
20. Ahmed SF, Khwaja O, Hughes IA. The role of a clinical score in the assessment of ambiguous genitalia. BJU Int 2000, 85:120–124.
21. Menten B, Pattyn F, De Preter K, Robrecht P, Michels E, Buesy K, Morlot G, De Peene S, Van Voorzen S, Vermeesch J, Moroue F, De Moor B, Vermeulen S, Speleman F, Vandesompele J. arrayCGHbase: an analysis platform for comparative genomic hybridization microarrays. BMC Bioinformatics 2005, 6:124.
22. Walter KN, Kienzle FB, Frankenschmidt A, Hiort O, Wudy SA, van der Werf-Baetens M, van de Merwe-Jansen S, Muller J-B, Brauner R, Lourenço D, Boudjene R, Karageorgou V, Trivin C, Lottmann H, Trivin C, Lottat-Jacob S, Nihoul-Fekete C, De Dreux O, McIlreavey K, Barbashnoo A. Mutation analysis of NR5A1 encoding steroidogenic factor 1 in 77 patients with 46, XY disorders of sex development (DSD) including hypospadias. PLoS One 2011, 6:e22941.
23. Brauner R, Neve M, Allali S, Trivin C, Lottmann H, Barbashnoo A, McIlreavey K. Clinical, biological and genetic analysis of anorachy in 26 boys. PLoS One 2011, 6:e22929.
24. Köhler B, Schumacher V, Fallmerand D, Rayer-Pokora B, Grütters A. Germline Wilms tumour suppressor gene (WT1) mutation leading to isolated genital malformation without Wilms tumour or nephropathy. J Pediatr 2001, 138:421–424.
25. Ledig S, Hiort O, Scherer G, Hoffmann M, Wolf G, Mörloth S, Kuechler A, Weacker P: Array-CGH analysis in patients with syndromic and non-syndromic XY gonadal disorder of sex development. PLoS One 2010, 5:e10291.
FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. Am J Hum Genet 2013, 92:75–743.

24. Cox K, Bryce J, Jiang J, Rodie M, Sinnot R, Akhavami M, Art W, Audl L, Balsamo A, Bertelli S, Cools M, Darendellier F, Drop S, Elliaisti M, Gurun T, Hort O, Holterman P, Hughes I, Kroner N, Lisa L, Morel Y, Soder O, Wreacker P, Ahmed SF: Novel associations in disorders of sex development: findings from the ENDOS Registry. J Clin Endocrinol Metab 2014, 99:1957–1959.

25. Grumbach MM: A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. J Clin Endocrinol Metab 2005, 90:3012–3017.

26. Boehmer A, Brinkmann A, Sandkuijl L, Halley D, Niermeijer M, Andersson S, Grumbach MM, A window of opportunity: the diagnosis of gonadotropin deficiency in the male infant. J Clin Endocrinol Metab 2005, 90:3012–3017.

27. Baldinotti F, Majore S, Fogli A, Marrocco G, Ghirri P, Vuerich M, Tumini S, Vizeneux A, Hilfiger A, Bouligand J, Pouillot M, Brailly-Tabard S, Bashamboo K, Baetens I-DSD Registry. J Clin Endocrinol Metab 2014, 99:7455–7457.

28. Kulle AE, Riepe FG, Melchior D, Hiort O, Holterhus PM: Variability, population genetics, and worldwide distribution of ancient I-DSD Registry. J Clin Endocrinol Metab 2014, 99:7455–7457.

29. Vizeneux A, Hilfiger A, Bouligand J, Pouillot M, Brailly-Tabard S, Bashamboo K, Baetens I-DSD Registry. J Clin Endocrinol Metab 2014, 99:7455–7457.

30. Lindhardt MH, Hansen CP, Johannsen TH, Main KM, Picard JY, Jørgensen A, Rajpert-De Meyts E, Juul A: Revisiting the androgen receptor gene: mutation screening and CAG repeat length analysis. Mol Hum Reprod 2013, 19:725–733.

31. Wang Y, Li Q, Xu J, Liu Q, Wang W, Lin Y, Ma F, Chen T, Li S, Shen Y: Mutation analysis of five candidate genes in Chinese patients with hypospadias. Eur J Hum Genet 2004, 12:706–712.

32. Allera A, Herbst M, Griffin J, Wilson J, McPhaul M: Mutations of the androgen receptor coding sequence are infrequent in patients with isolated hypospadias. J Clin Endocrinol Metab 1995, 80:2697–2699.

33. Quaynor SD, Kim H-G, Cappello EM, Williams T, Choi CP, Bick DP, Sherins N, Raynham E, Levitt S, Cousineau S, Newport M: Mutations in the IGF1 receptor gene in boys with hypospadias. Eur J Pediatr 1996, 155:171–174.

34. Alléra A, Herbst M, Griffin J, Wilson J, Schweikert H, McPhaul M: Mutations in the androgen receptor gene in boys with hypospadias. Eur J Pediatr 1996, 155:171–174.

35. Muroya K, Sasagawa I, Suzuki Y, Nakada T, Ishii T, Ogata T: Hypospadias and the androgen receptor gene: mutation screening and CAG repeat length analysis. Mol Hum Reprod 2001, 7:282–283.

36. Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP: Extensive clinical, hormonal and take full advantage of: Convenient online submission

37. Muroya K, Sasagawa I, Suzuki Y, Nakada T, Ishii T, Ogata T: Hypospadias and the androgen receptor gene: mutation screening and CAG repeat length analysis. Mol Hum Reprod 2001, 7:282–283.

38. Quaynor SD, Kim H-G, Cappello EM, Williams T, Choi CP, Bick DP, Sherins N, Raynham E, Levitt S, Cousineau S, Newport M: Mutations in the IGF1 receptor gene in boys with hypospadias. Eur J Pediatr 1996, 155:171–174.

39. Liu J, Li Y, Li S, Hu N, He Y, Peng R, Lin D, Lu L, Law M: Comparison of next-generation sequencing systems. J Biomed Biotechnol 2012, 2012:51364.

40. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

41. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

42. Naeve E, van Bokhoven H, Schröder R, Bader M, et al: Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med 2013, 369:1502–1511.

43. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

44. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

45. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

46. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

47. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

48. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

49. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.

50. Baetens I, Green RC, Ropers H-H, Hamel BCJ, Andres C, Barthélémy C, Moraine C, Briault S, Raynaud M, Ronce N, Lemonnier E, Calvas P, Laudier B, Chelly J, Fryns JP, Normosmic hypogonadotropic hypogonadism and Kallmann syndrome. Fertil Steril 2013, 96:1424–1430.